MedPath

Tyra Biosciences' FGFR3 Inhibitor TYRA-300 Shows Promise in Urothelial Cancer

• Tyra Biosciences' TYRA-300 demonstrated encouraging phase I/II data in metastatic urothelial cancer, offering a potential new treatment option. • The Surf301 trial results were described as 'fantastic' by analysts, highlighting the drug's potential clinical impact. • Despite positive data, Tyra Biosciences' stock experienced a significant drop, reflecting market uncertainty or profit-taking. • TYRA-300 targets FGFR3, a key player in urothelial cancer, representing a targeted approach to therapy.

Tyra Biosciences Inc. (NASDAQ:TYRA) presented phase I/II data for its FGFR3 inhibitor, TYRA-300, in metastatic urothelial cancer from the ongoing Surf301 trial. Despite the positive outcome, the company's shares closed down 23% on October 25, at $21.93.

Surf301 Trial Results

The Surf301 phase I/II study is evaluating TYRA-300 in patients with metastatic urothelial cancer. Preliminary data suggests promising activity of the drug. Tyler Van Buren, an analyst at TD Cowen, described the results as "fantastic," underscoring the potential clinical significance of TYRA-300 in this patient population.

TYRA-300: A Selective FGFR3 Inhibitor

TYRA-300 is a small molecule designed to selectively inhibit FGFR3, a receptor tyrosine kinase that plays a role in cell growth and differentiation. Aberrant FGFR3 signaling is implicated in the development and progression of urothelial cancer, making it a rational therapeutic target. The drug is designed to overcome resistance mechanisms that limit the effectiveness of existing FGFR inhibitors.

Urothelial Cancer Treatment Landscape

Urothelial cancer, primarily bladder cancer, represents a significant unmet medical need. While platinum-based chemotherapy remains a standard first-line treatment, many patients progress, highlighting the need for novel therapies. FGFR inhibitors have emerged as a targeted treatment option for patients with specific FGFR3 alterations. TYRA-300's data offers hope for patients with urothelial cancer.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Tyra Biosciences' TYRA-300 Shows Promise in Bladder Cancer and Achondroplasia

Tyra Biosciences reported positive interim Phase 1/2 data for TYRA-300 in metastatic urothelial cancer (mUC), with a 54.5% confirmed partial response rate in FGFR3+ patients.
The FDA cleared the IND for TYRA-300's Phase 2 study in pediatric achondroplasia (BEACH301), with the first patient expected to be dosed in Q1 2025.

Tyra Biosciences Stock Target Adjusted Following Clinical Data Review

H.C. Wainwright has adjusted Tyra Biosciences' stock price target to $30 from $32 while maintaining a Buy rating, following a review of clinical data for its lead compound, TYRA-300. The drug showed promising results in treating non-muscle-invasive bladder cancer and metastatic urothelial carcinoma, with a favorable safety profile.

Theralase Technologies Reports Promising Phase 2 Bladder Cancer Data and Outlines Funding Strategy

Theralase Technologies announced a 61.9% complete response rate in its Phase 2 bladder cancer study, with a 43.6% duration of response at 450 days.
The company plans to expand clinical study sites and increase patient enrollment to accelerate the completion of its Phase 2 bladder cancer study.

UroGen Pharma Advances Bladder Cancer Pipeline with UGN-102 and UGN-103

UroGen Pharma's New Drug Application for UGN-102, a treatment for non-muscle invasive bladder cancer, has been accepted by the FDA, with potential launch in 2025.
JELMYTO, UroGen's existing product, achieved $25.2 million in net sales in Q3, marking an increase from the previous year due to strong demand.

Tyra Biosciences' TYRA-300 Shows Promise in Metastatic Urothelial Cancer

TYRA Biosciences reported positive interim results for TYRA-300 in metastatic urothelial cancer (mUC) from the SURF301 Phase 1/2 study, demonstrating notable anti-tumor activity.
The company's IND was cleared for a Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301), with plans to initiate the study in Q1 2025.

TYRA-300 Shows Promise in FGFR3-Altered Urothelial Carcinoma

TYRA-300, a selective FGFR3 inhibitor, demonstrates encouraging anti-tumor activity in heavily pretreated metastatic urothelial carcinoma patients.
Interim Phase I/II SURF301 trial results show a 54.5% partial response rate in patients receiving at least 90 mg of TYRA-300 daily.

TYRA-300 Shows Promise in Treating Metastatic Bladder Cancer with FGFR3 Alterations

TYRA-300, a selective FGFR3 inhibitor, demonstrates promising antitumor activity in patients with metastatic urothelial cancer harboring FGFR3 alterations, with a 54.5% partial response rate at doses of 90 mg or higher.
The SURF301 trial's early results indicate that TYRA-300 is well-tolerated, with fewer of the adverse effects commonly associated with pan-FGFR inhibitors, offering a potentially improved safety profile.

FDA Clears Tyra Biosciences' Phase 2 Trial of TYRA-300 for Achondroplasia

The FDA has cleared Tyra Biosciences' Investigational New Drug (IND) application for TYRA-300, an oral FGFR3-selective inhibitor, to treat achondroplasia in children.
The Phase 2 BEACH301 study will evaluate TYRA-300's safety, tolerability, and impact on growth velocity in children aged 3 to 10 with achondroplasia.

TYRA-300: Novel FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer and Achondroplasia

TYRA-300 is a novel, orally available, and highly selective inhibitor of FGFR3, designed to minimize off-target toxicities associated with pan-FGFR inhibitors.
Phase 1 clinical trials are underway, evaluating TYRA-300 in patients with urothelial cancers and solid tumors harboring FGFR3 alterations.

Tyra Biosciences Initiates Phase 1/2 Trial of TYRA-300 in Metastatic Urothelial Carcinoma

Tyra Biosciences has commenced its SURF301 Phase 1/2 clinical trial, dosing the first patient with TYRA-300, an oral FGFR3-selective inhibitor.
The SURF301 study will evaluate TYRA-300's safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with metastatic urothelial carcinoma.

Reference News

[1]
Go FGFR: Tyra's urothelial data upbeat, stock down | BioWorld
bioworld.com · Oct 26, 2024

Tyra Biosciences' TYRA-300 FGFR3 inhibitor data in metastatic urothelial cancer deemed 'fantastic' by analyst, but stock...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy